Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats

Interactive Cardiovascular and Thoracic Surgery

Volumn 9, Issue 1, 2009, Pages 20-25

  Gäbel, Ralf ^a   Klopsch, Christian ^a   Furlani, Dario ^a   Yerebakan, Can ^a   Li, Wenzhong ^a   Ugurlucan, Murat ^a   Ma, Nan ^a,b   Steinhoff, Gustav ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Biomedizinischen Forschungszentrum (BMFZ)   (Germany)

Author keywords

Adverse effects; Angiogenesis; Cell cycle genes; Intracardiac proliferation; Myocardial ischemia

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 1; DOBUTAMINE; ERYTHROPOIETIN; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CAPILLARY DENSITY; CATHETER; CELL PROLIFERATION; CONFERENCE PAPER; CONTROL GROUP; CONTROLLED STUDY; DRUG SAFETY; HEART INFARCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE; HEART PERFORMANCE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE;

ANIMALS; CAPILLARIES; CARDIOTONIC AGENTS; CDC2 PROTEIN KINASE; CELL PROLIFERATION; CYCLIN D1; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; INJECTIONS, INTRALESIONAL; KI-67 ANTIGEN; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, INBRED LEW; RECOVERY OF FUNCTION; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 67650123224     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2008.191916     Document Type: Conference Paper

References (15)

1. Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006;101:31-39. (Pubitemid 43765334)
2. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806. (Pubitemid 36457809)
3. Van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen, DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133. (Pubitemid 40905140)
4. Klopsch C, Furlani D, Gaebel R, Wagner K, Li W, Ugurlucan M, Kundt G, Zingler C, Titze U, Wang W, Ong LL, Li RK, Ma N, Steinhoff G. Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J Cell Mol Med. Doi: 10.1111yj.1582-4934.2008.00546.x.
5. Richmond TD, Chohan M, Barbar DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-155. (Pubitemid 40332537)
6. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004;279:20655-20662. (Pubitemid 38656460)
7. Regula KM, Rzeszutek MJ, Baetz D, Senevratne C, Kirshenbaum LA. Therapeutic opportunities for cell-cycle reentry and cardiac regeneration. Cardiovasc Res 2004;64:395-401.
8. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3- kinase-dependent manner. Cardiovasc Res 2005;68:299-306. (Pubitemid 41428426)
9. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-5982. (Pubitemid 20240413)
10. Potente M, Michaelis UR, Fisslthaler B, Busse R, Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 2002;277:15671-15676. (Pubitemid 34967840)
11. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, Weinstein IB, Monden M. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res 2006; 12:4720-4729. (Pubitemid 44297826)
12. Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A. Cell cycledependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem 2006;281:7118-7128. (Pubitemid 43847476)
13. Ledda-Columbano GM, Molotzu F, Pibiri M, Cossu C, Perra A, Columbano A. Thyroid hormone induces cyclin D1 nuclear translocation and DNA synthesis in adult rat cardiomyocytes. FASEB J 2006;20:87-94. (Pubitemid 43100479)
14. Agah R, Kirshenbaum LA, Abdellatif M, Truong LD, Chakraborty S, Michael LH, Schneider MD. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium in vivo. J Clin Invest 1997;100:2722-2728. (Pubitemid 28007539)
15. Rossini A, Zacheo A, Mocini D, Totta P, Facchiano A, Castoldi R, Sordini P, Pompilio G, Abeni D, Capogrossi MC, Germani A. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol 2008;44:683-693.